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ABSTRACT
To achieve long-term disease-free survival, high-dose therapy and autologous stem cell transplantation
(ASCT) is the current standard approach in patients with relapsed or refractory Hodgkin disease (HD) or
non-Hodgkin lymphoma (NHL). Because chemosensitivity is a significant factor in determining transplanta-
tion eligibility, it is critical to select a salvage chemotherapy regimen that has the potential to induce a high
response rate with low nonhematologic toxicity. In this phase II study, 49 patients with relapsed or refractory
HD (n  22) and NHL (n  27) with a median age of 42 years were treated with an IIVP salvage regimen
consisting of ifosfamide, idarubicin, and etoposide. Twenty-seven percent of the patients had primary refrac-
tory disease, whereas 22% and 51% had early and late relapses, respectively. As analyzed by intention to treat,
16 patients (33%) achieved complete remission and 21 patients (43%) achieved a partial response, leading to
an overall response rate of 76% (63% in NHL and 91% in HD). In the univariate analysis, diagnosis (HD versus
NHL), remission duration before the initiation of IIVP, disease bulk, increased lactate dehydrogenase, and the
presence of “B” symptoms were significant factors affecting the response achieved by the IIVP regimen. Of 37
responders, 31 (84%) underwent high-dose therapy and transplantation. The probability of 4-year overall
survival (OS) and event-free survival (EFS) in this group of patients who underwent ASCT was 67.7% and
49.1%, respectively. When compared with the patients who achieved a partial response, patients who achieved
complete remission with the IIVP regimen had a significantly higher probability of 4-year EFS (67.3% versus
30%; P .016) and 4-year OS (92.3% versus 39.2%; P .003). In patients with HD, 4-year EFS and 4-year OS
were 54.9% and 70.6%, respectively, without a significant difference with respect to the survival rates obtained
in patients with NHL (43.6% and 63.6%, respectively). Common side effects observed during 102 cycles of
therapy were grade 3 to 4 neutropenia (62%) and thrombocytopenia (58%). The IIVP regimen is a highly
effective salvage regimen for patients with relapsed or refractory HD or NHL who are candidates for ASCT.
Furthermore, the degree of response to IIVP predicts the posttransplantation outcome. However, close
follow-up is necessary because of a high incidence of grade 3 to 4 hematologic toxicity.
© 2005 American Society for Blood and Marrow Transplantation
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HNTRODUCTION
Despite advances in therapy, 40% to 60% of pa-
ients with non-Hodgkin lymphoma (NHL) will not
chieve a complete remission (CR) or will relapse after
tandard ﬁrst-line therapy. Although most patients
ith Hodgkin disease (HD) will be cured with initial c
88herapy, 10% to 20% will not achieve a CR, and 20%
o 30% will relapse after standard therapy [1]. High-
ose chemotherapy (HDC) followed by autologous
tem cell transplantation (ASCT) is the treatment of
hoice for patients with relapsed or primary resistant
D or NHL [2-5]. The high rates of toxicity and
osts associated with HDC/ASCT demand that it be
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Beserved for patients in whom it clearly increases the
hance for cure compared with standard-dose therapy.
any studies have deﬁned chemosensitivity to con-
entional salvage chemotherapy as the most important
redictor of long-term event-free survival [4-6]. At
east a partial response (PR) to the salvage regimen is
equired to proceed with HDC and ASCT, to increase
he chance of achieving long-term survival [7,8]. Most
ommonly used salvage regimens—including DHAP
dexamethasone, cytarabine, and cisplatin), ESHAP
etoposide, methylprednisolone, cytarabine, and cis-
latin), and ICE (ifosfamide, carboplatin, and etopo-
ide)—can induce overall response rates (ORRs) rang-
ng between 40% and 60% [9-12]. The IIVP regimen,
onsisting of ifosfamide, idarubicin, and etoposide,
as previously reported as a salvage regimen with an
cceptable toxicity proﬁle for patients with relapsed or
efractory NHL or in small numbers of patients with
elapsed or refractory HD [13,14]. However, the ef-
ect of the IIVP regimen on transplantation has not
een reported.
An ideal pretransplantation salvage regimen is still
eing investigated to improve transplantation eligibil-
ty and outcome. In this study, the IIVP regimen was
dministered to patients with relapsed or refractory
ymphoma. The aims of this study were to determine
he efﬁcacy and toxicity of the regimen, to determine
he proportion of patients who would be able to pro-
eed with HDC/ASCT, and, ﬁnally, to determine the
utcome of ASCT on the basis of the response ob-
ained after the IIVP salvage regimen.
ATERIAL AND METHODS
atients
Forty-nine consecutive adult patients with re-
apsed or refractory NHL or HD were treated with
he IIVP salvage regimen at Hacettepe University
nstitute of Oncology between December 1999 and
uly 2004. Eligibility criteria included patients be-
ween 16 and 65 years of age, an Eastern Cooperative
ncology Group performance status of 3, and ade-
uate organ function, deﬁned by a serum creatinine
evel 2 mg/dL, serum transaminases 3 times the
ormal value, a bilirubin level of 2 mg/dL, a cardiac
jection fraction 50% as determined by echocardi-
graphy, an absolute neutrophil count 1.5  109/L,
nd a platelet count of 100  109/L. Patients were
equired to be free of central nervous system (CNS)
nvolvement, active infection, and human immunode-
ciency virus infection. Patients with a histology of
antle cell lymphoma or Burkitt or lymphoblastic
ymphoma were excluded. Also, patients with low-
rade histology, such as small lymphocytic lymphoma
r follicular lymphoma grade I and grade II, were
xcluded. A tumor size of 7 cm was classiﬁed as p
B&MTulky disease. All patients underwent staging proce-
ures before IIVP that included chest radiograph,
omputed tomography scans, and bone marrow bi-
psy. Gallium scanning was optional.
Primary refractory disease was deﬁned as disease
rogression or failure to attain a CR during ﬁrst-line
hemotherapy. CR was deﬁned as the disappearance
f all detectable clinical and radiographic evidence of
isease for 1 month. Early relapse required a CR
asting 12 months, and late relapse was deﬁned as a
R lasting 12 months.
All responding patients proceeded to stem cell
obilization and collection if they were eligible for
DC and stem cell transplantation. Eligibility criteria
or HDC/stem cell transplantation were age 60
ears, Eastern Cooperative Oncology Group perfor-
ance status 3, adequate pulmonary function (de-
ned as a forced expiratory volume in the ﬁrst second
nd diffusing capacity of carbon monoxide 60% of
redicted), and adequate cardiac, liver, and renal func-
ion. All patients signed informed consent forms be-
ore proceeding with HDC and ASCT.
alvage Protocol
The salvage regimen consisted of ifosfamide (1
/m2/d as a 1-hour infusion on days 1-5), mesna (200
g/m2 30 minutes before the infusion of ifosfamide
nd 4 and 8 hours after completion of ifosfamide on
ays 1-5), idarubicin (10 mg/m2/d as a 30-minute
nfusion on days 1-2), and etoposide (150 mg/m2/d
nfused over 2 hours on days 1-3), administered every
8 days. The regimen was administered on an inpa-
ient basis, and after completion of the regimen, pa-
ients were followed up on an outpatient basis. Pa-
ients were closely followed up for infectious,
ematologic, and nonhematologic toxicities. Antibac-
erial prophylaxis consisting of ciproﬂoxacin 500 mg
wice daily was given to patients with an absolute
eutrophil count 0.5  109/L. Patients were hospi-
alized if febrile neutropenia did not resolve within 48
ours with oral antibiotics or if they had symptoms or
igns of septicemia. As supportive measures, platelet
nd red blood cell transfusions and empirical intrave-
ous antibiotic therapy for neutropenic fever were
romptly commenced.
Patients who had a 50% to 75% reduction in
umor size after the second cycle received a third cycle
f the IIVP regimen, to achieve maximal cytoreduc-
ion before high-dose therapy and stem cell collection.
atients with progressive disease after the ﬁrst cycle
ere switched to an alternative salvage protocol.
se of Growth Factors
Because of the high incidence of neutropenic fever
pisodes observed in the ﬁrst 18 patients, primary
rophylaxis with granulocyte colony-stimulating fac-
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6or (G-CSF) at a dose of 5 g/kg/d was started 48
ours after the last dose of the salvage regimen until
ranulocyte recovery in the remaining 31 patients.
he median duration of G-CSF administration was 9
ays.
ssessment of Response
The response to therapy was assessed by physical
xamination of all palpable lymph node regions before
ach cycle and by computed tomography scans of the
nvolved sites after the second and third cycles of
IVP. Bone marrow biopsy was repeated if it was
ositive at baseline. Patients who underwent trans-
lantation were assessed on posttransplantation day
100 and every 3 months thereafter. Standard re-
ponse deﬁnitions previously deﬁned by the Interna-
ional Working Group were used [15].
ransplantation Protocol
The ASCT protocol consisted of 3 sequential
hases of HDC. Phase 1 consisted of cyclophospha-
ide (4.5 g/m2 given over two 1-hour administrations
t 3-hour intervals) followed by G-CSF (10 g/kg/d)
nd peripheral blood stem cell (PBSC) collection.
tem cell collection was initiated when the leukocyte
ount was 5000/L and was continued daily for 2 to
days until more than 2  106 CD34 cells per
ilogram were collected. Phase 2 consisted of etopo-
ide (2 g/m2 over 12 hours) with G-CSF support at 5
g/kg/d. The transplantation phase consisted of mi-
oxantrone (60 mg/m2 given over three 1-hour admin-
strations at 1-hour intervals on day 4) and melpha-
an (180 mg/m2 given over two 1-hour administrations
t 1-hour intervals on day 1) followed by PBSC
nfusion (day 0). G-CSF was initiated 4 hours after
BSC infusion. The interval between the phases was a
inimum of 21 days.
tatistical Analysis
Responses to the IIVP regimen were analyzed by
ntention to treat, but only patients who achieved at
east a PR to the IIVP regimen were eligible for
SCT. The primary end points of this study were
esponse rate (CR plus PR), ability to proceed with
ransplantation, and toxicity of the regimen. The sec-
ndary end points were the success rate of mobiliza-
ion and the outcome of transplantation. The outcome
ariables examined were (1) response rate to IIVP; (2)
verall survival (OS), deﬁned from the time of initia-
ion of IIVP chemotherapy to last follow-up evalua-
ion or death; and (3) event-free survival (EFS), de-
ned as achievement of a CR or PR from the time of
nitiation of IIVP chemotherapy until progression,
elapse, or death from any cause.
Statistical analysis was performed by using Stat-
iew for Windows (SAS Institute, Inc., Cary, NC) d
90ersion 5.0. Survival curves were estimated by using
he method of Kaplan and Meier [16]. Outcomes of
ifferent clinical and prognostic groups were com-
ared by using the 2-sided log-rank test [17]. Differ-
nces in response rates were analyzed by Fisher exact
est with the Yates continuity correction [18]. Because
f the small sample size, multivariate analysis was not
erformed. All probability values were 2 sided and
tatistically signiﬁcant when P  .05.
ESULTS
atient Characteristics
Patient characteristics before the initiation of
IVP are listed in Table 1. The median age of the
atients was 42 years (range, 16-65 years), and 7 (14%)
atients were older than 60 years of age.
Among NHL patients, diffuse large B-cell lym-
homa was the most common histology (n  22;
1%), followed by follicular lymphoma grade III (n 
), anaplastic large cell lymphoma (n  1), peripheral
-cell lymphoma (n  1), and natural killer/T-cell
ymphoma (n  2). Of the 27 NHL patients, 4 (15%)
ad a T-cell phenotype. Most patients with HD had
ither nodular sclerosis (n  10) or mixed cellularity
n  10) histology. All patients had experienced treat-
ent failure with at least 1 anthracycline-based regi-
en. Half of the patients had primary refractory dis-
ase (27%) or early relapse (22%). Of patients with
elapsed disease (n  36), 67% were at their ﬁrst
elapse, and 33% were beyond ﬁrst relapse. Eighty-six
ercent of patients (n  42) received either 2 or 3
ycles of IIVP. Three patients with progressive disease
fter the ﬁrst cycle of IIVP had to switch to an alter-
ative salvage regimen.
esponse to Chemotherapy and Factors
nfluencing Response
Response to the IIVP regimen was not evaluable
n 3 patients because of toxic death (n  2) and a
erious adverse event leading to discontinuation of the
herapy after the ﬁrst cycle. Nine patients did not
espond to IIVP. As analyzed by intention to treat, 16
atients (33%) achieved CR and 21 patients (43%)
chieved PR, leading to an ORR of 76% (Figure 1).
actors predicting response to IIVP are depicted in
able 2. Remission duration (late relapse, early re-
apse, and primary refractory disease) before the ini-
iation of IIVP was found to be a signiﬁcant factor for
esponse to IIVP (P  .0001; 2 for independence,
8.6). The best ORR was achieved in patients with
ate relapse (100%), followed by early relapse (64%)
nd primary refractory disease (38%; Figure 2). In
ddition, patients with nonbulky disease (P  .022),
ithout “B” symptoms (P .011), with normal lactate
ehydrogenase (P  .035), and with HD (P  .043)
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Bad a better response to IIVP. There was no statisti-
ally signiﬁcant difference between the response rates
f patients with a single relapse and patients with
ore than 1 relapse.
Patients with NHL. Eight (30%) patients achieved
R, and 9 (33%) patients achieved PR, corresponding
o an ORR of 63%. Factors predicting the response to
IVP were remission duration, disease bulk, lactate
ehydrogenase level, presence of B symptoms, and
ge-adjusted International Prognostic Index (Table 3).
xcept for 3 patients, all responding patients pro-
eeded to stem cell transplantation. In addition, 1
atient who was refractory to IIVP responded to an
lternative salvage regimen and underwent ASCT.
Patients with HD. Twenty-two patients with HD
ad an ORR of 91%, consisting of 36% CR and 55%
R. The only signiﬁcant factor that inﬂuenced re-
ponse to IIVP was remission duration (primary re-
ractory versus relapse, P  .043; odds ratio, 25; 95%
onﬁdence interval, 0.97-642). Whereas all relapsed
atients responded to the IIVP salvage regimen, 40%
f primary refractory patients remained resistant. All
ut 3 responding patients proceeded to ASCT.
ransplantation Data
Of the 37 responders, 31 (84%) underwent HDC
nd transplantation. Two responding patients refused
able 1. Patient Characteristics
Characteristic NHL
edian age, y (range) 48
ex
Male 17
Female 10
tage
I, II 16
III 5
IV 6
ncreased serum LDH 13
emission duration before initiation of IIVP
Primary refractory 8
Relapse 19
Duration of previous response
Early relapse (<12 mo) 9
Late relapse (>12 mo) 10
No. relapses
First relapse 17
Second relapse 2
Third relapse and beyond 0
rognostic score for NHL*
Low 9
Low-intermediate 8
High-intermediate 9
High 1
o. IIVP cycles administered
1 6
2 14
3 7
DH indicates lactate dehydrogenase.
According to an age-adjusted International Prognostic Index.igh-dose therapy; 2 patients were ineligible for u
B&MTSCT because of their concomitant systemic diseases,
nd 1 patient was ineligible because of age 60 years.
ne responding patient relapsed before initiation of
he third phase of the high-dose sequential chemo-
herapy protocol. Of the 6 patients who did not un-
ergo transplantation, none is alive. The median EFS
nd OS of these patients were 5.2 and 8 months,
espectively. Of the 9 patients refractory to IIVP, 1
esponded to a second-line salvage therapy and even-
ually proceeded to ASCT. This patient is currently
live and free of disease.
igure 1. Response to the IIVP regimen in the entire group and in
atients with NHL and HD. CR indicates complete response; PR,
artial response. No response* includes treatment-resistant and
27) HD (n  22) Total (n  49)
) 36 (16-65) 42 (16-65)
15 (68%) 32 (65%)
7 (32%) 17 (35%)
7 (32%) 23 (47%)
9 (41%) 14 (28%)
6 (27%) 12 (25%)
10 (48%) 23 (51%)
5 (23%) 13 (27%)
17 (77%) 36 (73%)
2 (9%) 11 (22%)
15 (68%) 25 (51%)
7 (32%) 24 (49%)
7 (32%) 9 (18%)
3 (13%) 3 (6%)
—
—
—
—
1 (5%) 7 (14%)
17 (77%) 31 (63%)
4 (18%) 11 (23%)(n 
(26-64
(63%)
(37%)
(59%)
(19%)
(22%)
(54%)
(30%)
(70%)
(33%)
(37%)
(63%)
(7%)
(0%)
(33%)
(30%)
(33%)
(4%)
(22%)
(52%)
(26%)nevaluable patients.
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6nalysis of ASCT
One patient who was refractory to IIVP but un-
erwent ASCT after responding to second-line sal-
age therapy was not included in the analysis. None of
he patients experienced mobilization failure during
tem cell collection. A median of 8.3  106 CD34
ells per kilogram (range, 2-18) was collected.
After ASCT, 7 patients relapsed or progressed, and 8
atients died. Mortality was secondary to relapsed or
rogressive disease (n  4), ASCT toxicity (n  2),
ongestive heart failure (n  1), and secondary acute
yeloblastic leukemia (AML; n  1).
igure 2. Response to the IIVP regimen according to remission
uration before the initiation of IIVP. CR indicates complete re-
ponse; PR, partial response. No response* includes treatment-
able 2. Factors Inﬂuencing Response to IIVP (n  49)
Factor
Response, n (%)
CR  PR Resistan
ex
Male 24 (75) 8 (25
Female 13 (76) 4 (24
iagnosis
HD 20 (91) 2 (9)
NHL 17 (63) 10 (37
emission duration
Primary refractory 5 (38) 8 (62
Early relapse 7 (64) 4 (36
Late relapse 25 (100) 0 (0)
ulky disease
No 29 (88) 4 (12
Yes 8 (53) 7 (47
B” symptoms
Absent 18 (90) 2 (10
Present 8 (50) 8 (50
DH
Normal 20 (91) 2 (9)
High 14 (61) 9 (39
tage
I-III 30 (81) 7 (19
IV 7 (58) 5 (42
DH indicates lactate dehydrogenase; CI, conﬁdence interval.
Chi-square for independence.
Identical results in both groups leads to a P value of 1.sesistant and unevaluable patients.
92urvival Analysis of ASCT
The median follow-up time for patients who re-
ponded to IIVP and underwent ASCT was 31
onths. The probability of 4-year OS and 4-year EFS
as 67.7% and 49.1%, respectively. When compared
ith patients who achieved PR, patients who attained
R to IIVP had a signiﬁcantly higher probability of
-year EFS (67.3% versus 30%; P  .016) and 4-year
S (92.3% versus 39.2%; P .003; Figure 3). Patients
ho experienced treatment failure with IIVP had a me-
ian survival of only 5 months. In patients with HD,
-year EFS and 4-year OS were 54.9% and 70.6%,
espectively, without a signiﬁcant difference with respect
o survival rates obtained in patients with NHL (43.6%
nd 63.6%, respectively). Remission duration before
IVP did not predict the outcome of ASCT.
oxicity
Patients received a total of 102 cycles of IIVP. The
oxicity proﬁle of the regimen is summarized in Table
. The toxicity proﬁle was not different between pa-
ients with HD and NHL. The most common side
ffects were grade 3 to 4 neutropenia (observed in
2% of the cycles) and grade 3 to 4 thrombocytopenia
in 58%). Febrile neutropenia was observed in 38% of
he cycles. Only 1 patient developed grade 4 infection.
ospitalization due to febrile neutropenia was neces-
P value Odds Ratio 95% CI
1.00† — —
.043 5.9 1.13-30.65
<.0001 18.6*
.022 6.3 1.48-27.23
.011 9.0 1.55-52.29
.035 6.4 1.20-34.42
.14 — —ce
)
)
)
)
)
)
)
)
)
)
)
)ary in 31% of the cycles. The administration of sec-
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Bnd and third cycles was delayed in 4 patients because
f febrile neutropenia. There was no evidence of in-
reasing rates of febrile neutropenia during the con-
equent cycles. Because a high incidence of febrile
eutropenia was observed (72%) in the ﬁrst 18 pa-
ients, primary prophylaxis with G-CSF in the re-
aining patients was initiated. All of the ﬁrst 18 pa-
ients who did not receive growth factor support stayed
n schedule. The mean number of single-donor platelet
nd erythrocyte transfusions for each cycle was 1.5
range, 0-7) and 0.8 (range, 0-5), respectively.
None of the patients experienced a decrease in car-
iac ejection fraction or arrhythmia associated with an-
hracycline use during or after IIVP. No hemorrhagic
ystitis or renal toxicity was observed throughout the
tudy period. Three patients developed CNS toxicity
posterior leukoencephalopathy syndrome, confusion,
nd nonconvulsive status epilepticus) related to ifosfa-
ide. CNS toxicity was reversible in 2 patients. Two
oxic deaths (4%), 1 due to CNS toxicity (posterior
eukoencephalopathy syndrome) and another due to tu-
or lysis syndrome, occurred after IIVP. Compared
ith the ﬁrst cycle, no increase in the incidence or
able 3. Factors Predicting Response to IIVP in NHL Patients (n  2
Factor
Response, n
CR  PR
emission duration
Late relapse 10 (100)
Primary refractory or early relapse 7 (41)
ulky disease
No 15 (83)
Yes 2 (25)
DH
Normal 10 (91)
High 5 (38)
B” symptoms
Absent 9 (90)
Present 2 (22)
A-IPI
Low and low-intermediate 14 (82)
High-intermediate and high 3 (30)
I indicates conﬁdence interval; LDH, lactate dehydrogenase; AA-Figure 3. Probability of overall survival (A) and event-free survival (B
B&MTeverity of toxicities was observed throughout the con-
equent cycles.
As a posttransplantation complication, 3 patients
eveloped congestive heart failure (1 was severe),
ainly because of high cumulative doses of anthracy-
lines during the previous treatments coupled with
igh-dose mitoxantrone exposure in the conditioning
egimen, although the contribution of idarubicin in
he IIVP regimen could not be excluded. One of the
atients who developed congestive heart failure had a
iagnosis of thalassemia intermedia, and transfusion-
elated hemochromatosis contributed to congestive
eart failure. Other complications of the transplanta-
ion procedure were myeloid engraftment failure in 1
atient, leading to sepsis and death; delay in platelet
ngraftment in 1 patient; myelodysplastic syndrome in
patient; and secondary AML in 1 patient. None of
he patients developed veno-occlusive disease.
ISCUSSION
The grave prognosis in patients with relapsed or
efractory NHL or HD who do not receive or are
P Value Odds Ratio 95% CIance
0) .003 29.4 1.48-583.78
59)
17) .008 15.0 1.98-113.61
75)
9) .013 16.0 1.54-166.14
62)
10) .006 31.5 2.35-422
78)
18) .013 10.9 1.73-68.6
70)
e-adjusted International Prognostic Index.7)
(%)
Resist
0 (
10 (
3 (
6 (
1 (
8 (
1 (
7 (
3 (
7 () separated by IIVP response in patients undergoing ASCT.
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6ot eligible for HDC and ASCT is well known
4,5,8,19,20]. In this study, a combination of ifosfa-
ide, etoposide, and idarubicin was utilized as the
alvage regimen to obtain high response rates in order
o improve eligibility for ASCT. Because chemosen-
itivity is a prerequisite for transplantation eligibility
n most patients with relapsed or refractory lym-
homa, an important variable affecting outcome in
atients with relapsed or refractory lymphoma is the
ytoreductive capacity of the salvage regimen before
SCT. Because of the lack of randomized studies
omparing salvage regimens, it is not possible to in-
erpret one as superior to another. Thus, it is critical
o select a salvage regimen that has the potential to
nduce a high response rate with low nonhematologic
oxicity, without cumulative myelosuppression that
ay subsequently impair stem cell collection.
Salvage regimens are designed in anticipation of
esistance to previously used chemotherapy regimens.
nthracyclines are one of the most effective drug
roups against lymphoma. Because of a lack of cross-
esistance between idarubicin and other anthracy-
lines, patients who develop resistance to doxorubicin
ay still respond to subsequent idarubicin therapy
21]. The mdr-1 gene overexpression is strongly asso-
iated with the development of a high level of resis-
ance to doxorubicin, but not to idarubicin [22]. In
reviously untreated lymphoma patients, regimens
ontaining idarubicin 10 mg/m2 were shown to have
he same efﬁcacy as regimens containing doxorubicin,
ith slightly lower toxicity [23]. In patients with re-
apsed or refractory lymphoma who had prior anthra-
ycline exposure, idarubicin combinations proved to
e active salvage therapies, with response rates rang-
ng between 47% and 72% [13,24,25]. Ifosfamide can
licit responses in patients refractory to cyclophospha-
ide and has been shown to be active in experimental
umor models resistant to anthracyclines or cyclo-
hosphamide [26-28].
The following ﬁndings emerge from this phase II
rial. (1) IIVP is an effective salvage chemotherapy
egimen with acceptable nonhematologic toxicity be-
ore high-dose sequential chemotherapy and ASCT in
atients with relapsed or refractory HD or NHL. (2)
cute hematologic toxicity is manageable and revers-
ble but warrants close follow-up. (3) The regimen is
able 4. WHO Grade 3/4 Hematologic Toxicity of the IIVP Regimen
Toxicity (WHO Grade 3-4) NHL (n  55)
eutropenia 34 (62%)
ebrile neutropenia 21 (38%)
Treated inpatient 17 (31%)
hrombocytopenia 32 (58%)
nemia 9 (16%)
HL indicates non-Hodgkin lymphoma; HD, Hodgkin disease; Wffective, with a satisfactory ORR of 76% (63% in w
94HL and 91% in HD). (4) Remission duration before
he initiation of IIVP (primary refractory versus early
elapse versus late relapse) is a major factor in predict-
ng response. (5) Response to IIVP (CR versus PR)
redicts OS and EFS in patients undergoing ASCT,
o efforts should be taken to increase the rate of CR
chieved with IIVP. (6) The response in patients with
rimary refractory disease is 38%, which alerts us to
he urgent need for the development of novel strate-
ies in this group of patients.
The high response rate to IIVP compares favor-
bly to the results obtained with the commonly used
retransplantation salvage regimens, including
HAP, Mini-BEAM/Dexa-BEAM (carmustine, eto-
oside, cytarabine, and melphalan with or without
examethasone), and ICE [12,29-34]. ICE yields re-
ponse rate of 66% and a CR rate of 24% [12]. In
ddition to ICE, several ifosfamide/etoposide-based
egimens have been used as salvage therapy. The
RRs and CR rates achieved with dexamethasone,
fosfamide, carboplatin, and etoposide are 73% and
1% in patients with NHL [35]; with ifosfamide,
pirubicin, etoposide, they are 77% and 32% in pa-
ients with NHL and 81% and 45% in patients with
D [36]; and with dexamethasone, ifosfamide, idaru-
icin, and etoposide, they are 58% and 26% in pa-
ients with NHL/HD [24]. One of the most important
actors predicting response to IIVP was prior remis-
ion duration. The response rate was 100% in late
elapse, 64% in early relapse, and 38% in primary
esistance disease. Similarly, several studies have re-
orted remission duration as the predictive factor for
esponse to salvage regimens [30,34,37-39]. However,
n contrast to the literature [32,39-41], this was not a
rognostic factor for survival in our transplantation
atients. Although this study was not powered to de-
ect modest differences, it can be speculated that the
oor prognostic effect of remission duration may dis-
ppear among patients who respond to IIVP salvage
herapy.
In this study, the degree of response (CR versus
R) achieved with the IIVP regimen before the initi-
tion of HDC showed a signiﬁcant effect on post-
ransplantation outcome. Similarly, in several studies,
atients who underwent transplantation in CR were
emonstrated to have better outcomes than patients
f 102 Courses)
HD (n  47) Total (n  102)
29 (62%) 63 (62%)
12 (26%) 33 (32%)
10 (21%) 27 (26%)
26 (55%) 58 (57%)
7 (15%) 16 (16%)
orld Health Organization.(Total oho underwent transplantation in PR [8,12,40]. This
o
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Bbservation suggests that (1) the quality of response to
alvage chemotherapy is an expression of degree of
hemosensitivity of lymphoma, and a lymphoma in-
uced into CR by salvage chemotherapy inherently is
ore likely than a lymphoma induced into PR to be
radicated by high-dose therapy; (2) the efﬁcacy of
igh-dose therapy may be affected by tumor burden;
hus, the potentiating response to the salvage regimen
ay improve the outcome of HDC.
In patients with relapsed or refractory NHL, CR
ates obtained with commonly used salvage chemo-
herapy regimens (DHAP, ESHAP, Mini-BEAM, and
CE) range from 25% to 35% [9,29,37,42,43]. Ritux-
mab, in addition to its antitumor effect that leads to
esponses in approximately 30% to 35% of patients
ith relapsed or primary refractory NHL [44], sensi-
izes tumor cells to the effects of chemotherapy. The
ddition of rituximab to the cyclophosphamide, doxo-
ubicin, vincristine, and prednisone regimen signiﬁ-
antly increases the CR rate among patients with pre-
iously untreated diffuse large B-cell lymphoma [45].
hen added to ICE, rituximab doubles the CR rate in
atients with relapsed or primary refractory diffuse
arge B-cell lymphoma [30]. Therefore, adding ritux-
mab to IIVP may augment both overall response and
R rates. Currently, a phase II study of rituximab and
IVP in patients with B-cell NHL has been initiated at
ur institution to answer this question.
In the light of these results, our future goals while
esigning a salvage regimen should be to increase the
RR for more patients to be eligible for HDC and to
ncrease the CR rate to obtain a better outcome after
SCT. At present, these goals can be accomplished by
ombining biotherapy (monoclonal antibodies) with
hemotherapeutics.
The treatment-related toxicity of IIVP was mainly
ematologic and reversible. Myelosuppression was
rofound but relatively brief. Despite the use of anti-
iotic prophylaxis and G-CSF support, neutropenic
ever and uncomplicated bacteremias frequently oc-
urred. However, no life-threatening complications or
eaths due to infectious complications were observed
n this study. The grade 4 thrombocytopenia and
rade 4 neutropenia reported with ICE were 47% and
3%, respectively, which were not much different
rom those with the IIVP regimen [46]. Cumulative
yelosuppression that might subsequently impair the
arvesting of sufﬁcient stem cells was not seen. The
ajor life-threatening toxicity of IIVP was ifosfamide-
nduced encephalopathy, and this was fatal in 1 pa-
ient. We think that this risk can be minimized by the
dministration of ifosfamide as a 24-hour infusion
12]. Some currently used salvage regimens can pro-
uce severe and irreversible nonhematologic toxicities
hat might prevent patients from proceeding to
B&MTSCT. DHAP and ESHAP may cause renal insufﬁ-
iency, deﬁned as a doubling of the patient’s serum
reatinine level, in nearly 20% of patients [4,47] and
ife-threatening hypomagnesemia. In addition, both
egimens were associated with toxic deaths of more
han 5% [9,10,48]. Stem cell mobilization after regi-
ens containing high-dose cytarabine (DHAP) or
ontaining stem cell–toxic chemotherapeutic agents
uch as carmustine and melphalan (Mini-BEAM or
exa-BEAM) may adversely affect stem cell collec-
ions [48-50].
Two patients with HD developed secondary ma-
ignancy during follow-up. One had a treatment his-
ory of 22 years, including radiotherapy, experienced 3
elapses before the IIVP salvage regimen, and even-
ually developed myelodysplastic syndrome. The sec-
nd patient, who developed AML, had had 2 relapses
efore IIVP and has received radiotherapy. Thus, use
f HDC/ASCT earlier, at the time of ﬁrst relapse,
ather than after multiple recurrences may reduce the
isk of secondary malignancies.
In conclusion, IIVP is an effective salvage chemo-
herapy regimen with acceptable toxicity and without
dverse effects on PBSC mobilization in patients with
elapsed or refractory NHL and HD. In addition to
etermining patients who qualify for ASCT, the de-
ree of response to IIVP predicts long-term outcome
fter autologous transplantation.
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